| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 12/21/2006 | WO2004078143A3 Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs |
| 12/21/2006 | WO2004020578A3 Glycosylation modified il-20 |
| 12/21/2006 | WO2003091409A3 Identification of compounds which stimulate bone formation using a cell-based screening assay targeting bmp signaling |
| 12/21/2006 | WO2003054144A3 Human ras interacting protein |
| 12/21/2006 | US20060288456 Technique for extending biological sugar chain via introduction of glycosyltransferase gene |
| 12/21/2006 | US20060288455 modifying plant gene expression and/or by modifying plant haemoglobin levels in a plant; genetic engineering; altering tolerance in plants to various environmental stresses and to increasing seed yield |
| 12/21/2006 | US20060288454 Plants having modified growth characteristics and method for making the same |
| 12/21/2006 | US20060288453 Nucleotide sequences coding polypeptide for use in enhancing digestibility of plants, improving gum extractability from plants, and altering plant propagation |
| 12/21/2006 | US20060288452 Expression vector comprising nucleotide sequences coding regulatory sequences associated with ADP-glucose pyrophosphorlyase gene for use as tool in controlled transcription of heterologous protein in plant storage roots |
| 12/21/2006 | US20060288451 Elevation of oil in monocot plants |
| 12/21/2006 | US20060288450 Plant N-acylethanolamine binding proteins |
| 12/21/2006 | US20060288449 Process for purifying target compounds from plant sources using ceramic filtration |
| 12/21/2006 | US20060288448 nucleotide sequence encoding Bacillus thuringiensis Cry8Bb1 protoxin, has at least one proteolytic activation site that has been engineered to comprise a cleavage site that is sensitive to an insect gut cysteine protease; transgenic seed and plant |
| 12/21/2006 | US20060288447 Method for disease control in MON89788 soybean |
| 12/21/2006 | US20060288446 cell comprising an endochitinase, a stilbene synthase and a superoxide dismutase; encoded from a nucleic acid construct which comprises an internal ribosome entry site sequence; confer resistance to sigatoka |
| 12/21/2006 | US20060288445 P15 hairpin constructs and use |
| 12/21/2006 | US20060288444 Soybean polymorphisms and methods of genotyping |
| 12/21/2006 | US20060288443 Glutamine-rich maize seed protein and promoter |
| 12/21/2006 | US20060288442 Use of mixed duplex oligonucleotides to effect localized genetic changes in plants |
| 12/21/2006 | US20060288441 nucleotide sequence or complements that code polypeptides having synthetase enzyme activity, used to alter enzyme levels in transformed host cells |
| 12/21/2006 | US20060288440 Nucleotide sequences mediating male fertility and method of using same |
| 12/21/2006 | US20060288439 Leaf-specific chlorophyll A/B binding protein promoter |
| 12/21/2006 | US20060288438 Novel miniature inverted-repeat transposable elements (MITEs)-like element and transcriptional activation element |
| 12/21/2006 | US20060288437 Zinc finger-based drug-dependent gene regulation system |
| 12/21/2006 | US20060288436 Screening systems and methods for identifying modulators of xenobioticmetabolism |
| 12/21/2006 | US20060288435 CD9/CD81 double-deficient non-human animal |
| 12/21/2006 | US20060288434 Inhibiting angiogenesis in a mammal by administering an antibody which specifically binds to EphriniB2 or EphB4; cardiovascular disorders |
| 12/21/2006 | US20060288433 Selecting a domestic animal for having desired genotypic properties bytesting the animal for the presence of a parentally imprinted quantitative trait locus; particularly selecting properties related to muscle mass, fat deposition, sow prolificacy, and/or sow longevity in pigs |
| 12/21/2006 | US20060287514 Mammalian cytokine-like polypeptide-10 |
| 12/21/2006 | US20060287513 Compositions and methods for the therapy and diagnosis of breast cancer |
| 12/21/2006 | US20060287508 Methods for stabilizing proteins |
| 12/21/2006 | US20060287507 Mammalian cytokine-like polypeptide-10 |
| 12/21/2006 | US20060287505 Of given amino acid sequence; useful for promoting wound healing and stimulating platelet proliferation; can use in treating autoimmune diseases and cancer |
| 12/21/2006 | US20060287504 Universal procedure for refolding recombinant proteins |
| 12/21/2006 | US20060287503 Analyzing fusion protein expression; biological screening |
| 12/21/2006 | US20060287502 C3b/C4b complement receptor-like molecules and uses thereof |
| 12/21/2006 | US20060287501 Soluble truncated polypeptides of the nogo-a protein |
| 12/21/2006 | US20060287432 Peptide purification by means of metal ion affinity chromatography |
| 12/21/2006 | US20060287270 Methods of using redox-active surfactants to control polymer interactions |
| 12/21/2006 | US20060287269 Short interfering nucleic acid hybrids and methods thereof |
| 12/21/2006 | US20060287268 Splice-region antisense composition and method |
| 12/21/2006 | US20060287266 Synthesizing a double stranded nucleic acid molecule used for treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability |
| 12/21/2006 | US20060287265 Apoptosis-specific eIF-5A and polynucleotides encoding same |
| 12/21/2006 | US20060287261 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| 12/21/2006 | US20060287260 Oligonucleotides comprising a non-phosphate backbone linkage |
| 12/21/2006 | US20060287259 Compositions and methods for combined therapy of disease |
| 12/21/2006 | US20060287258 administering to the female an antibody that reduces the effect of prokineticin 1 on a prokineticin receptor to treat endometriosis; gonadotropin releasing hormone (GnRH) antagonist is selected from teverelix, abarelix, cetroelix or ganirelix antagonises the estrogen receptor |
| 12/21/2006 | US20060287236 Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases |
| 12/21/2006 | US20060287230 Compositions which can be used for regulating the activity of parkin |
| 12/21/2006 | US20060287228 Expression of active human factor IX in mammary tissue of transgenic animals |
| 12/21/2006 | US20060287226 Characterization of a membrane estrogen receptor |
| 12/21/2006 | US20060287223 Remodeling and glycoconjugation of peptides |
| 12/21/2006 | US20060286671 Efficient generation of expression cell lines through the use of scorable homeostatic reporter genes |
| 12/21/2006 | US20060286656 Characterization of the I-SpomI endonuclease from fission yeast |
| 12/21/2006 | US20060286653 Transforming bacterial cell with exogenous gene encoding protein having glycerol-3-phosphate dehydrogenase and phosphatase activity; gene expression inhibition of polypeptide encoding glycerol kinase |
| 12/21/2006 | US20060286652 Gene that encodes a protein having a function of enhancing temperature tolerance derived from a microorganism |
| 12/21/2006 | US20060286651 Increasing perhydrolase activity in esterases and/or lipases |
| 12/21/2006 | US20060286650 Vector capable for transformation of labyrinthulomycota |
| 12/21/2006 | US20060286649 Enhanced production of lipids containing polyenoic fatty acid by very hugh density cultures of eukaryotic microbes in fermentors |
| 12/21/2006 | US20060286648 Propagating thraustochytriales and using as bioreactors for fermentation of polyunsaturated fatty acids (docosahexaenoic acid ); aerobic processing |
| 12/21/2006 | US20060286645 Polynucleotide constructs for increased lysine production |
| 12/21/2006 | US20060286644 Using recombinant microorganisms in which the open reading frame (ORF) designated ytfQ is enhanced in particular overexpressed; fermentation |
| 12/21/2006 | US20060286643 Method for producing L-amino acid using bacterium of Enterobacteriaceae family having expression of yafA gene attenuated |
| 12/21/2006 | US20060286640 Process for production of polypeptides |
| 12/21/2006 | US20060286635 Albumin fusion proteins |
| 12/21/2006 | US20060286634 Vector |
| 12/21/2006 | US20060286633 Methods for production of proteins |
| 12/21/2006 | US20060286631 Method for preparating t-20 peptide by high cell density cultivation of recombinant e. coli containing t-20 peptide coding gene |
| 12/21/2006 | US20060286610 Identification of ligands by selective amplification of cells transfected with receptors |
| 12/21/2006 | US20060286607 Isolating nucleic acid encoding a plant polypeptide for use in generating disease resistant plants; obtain library, incubate with probe, recover clone, transform plant, propagate, evaluate for disease resistance |
| 12/21/2006 | US20060286600 High throughput one-hybrid system |
| 12/21/2006 | US20060286596 Method and apparatus for separating and purifying biopolymers |
| 12/21/2006 | US20060286592 Increased ability to convert 5-fluorocytosine prodrug to its toxic form |
| 12/21/2006 | US20060286581 Heteroconfigurational Polynucleotides and Methods of Use |
| 12/21/2006 | US20060286568 Analyzing nucleic acid sample for a deletion in nucleotide sequence; sequencing a portion of the spinocerebellar ataxia type 5 (SCA5) polynucleotide; neurodegenerative diseases; diagnosis; hybridization |
| 12/21/2006 | US20060286567 Salicylamide-lanthanide complexes for use as luminescent markers |
| 12/21/2006 | US20060286562 Methods for purifying DNA polymerases |
| 12/21/2006 | US20060286561 Propargylethoxyamino nucleotides |
| 12/21/2006 | US20060286545 Viral vectors with improved properties |
| 12/21/2006 | US20060286125 Immunomodulation; Yatapoxvirus polypeptide; multiple sclerosis, psoriasis, atopic dermatitis, type 1 insulin-dependent diabetes mellitus, dermatitis, Sjoigren's syndrome, encephalitis, Reiter's syndrome, psoriatic arthritis, progressive systemic sclerosis, primary biliary cirrhosis |
| 12/21/2006 | US20060286124 Vaccine compositions and methods of treating coronavirus infection |
| 12/21/2006 | US20060286121 Adenoviral vector-based vaccines |
| 12/21/2006 | US20060286118 Lawsonia intracllularis subunit vaccine |
| 12/21/2006 | US20060286114 Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof |
| 12/21/2006 | US20060286110 Bax-responsive genes for drug target identification in yeast and fungi |
| 12/21/2006 | US20060286109 Compositions and vaccines containing antigen(s) of Cryptosporidium parvum and of another pathogen |
| 12/21/2006 | US20060286091 RelA-ASSOCIATED INHIBITOR, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF |
| 12/21/2006 | US20060286087 Recombinant alpha-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| 12/21/2006 | US20060286085 Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods |
| 12/21/2006 | US20060286083 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
| 12/21/2006 | US20060286082 Systems and methods for generating biological material |
| 12/21/2006 | US20060286080 Method for obtaining plasmid-dna by means of an aqueous biphasic system |
| 12/21/2006 | US20060286074 Methods for immunotherapy of cancer |
| 12/21/2006 | US20060286073 COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
| 12/21/2006 | US20060286072 A replication-defective adenoviral or adeno-associated viral vector; gene therapy for congestive heart failure; antiischemic agents |
| 12/21/2006 | US20060286070 for extending clinical utility of interferon (IFN) alpha in treatment of a variety of viral and proliferative disorders; increase efficacy of IFN- alpha and reduce IFN- alpha treatment-related side effects |
| 12/21/2006 | US20060286069 G-CSF Conjugates |
| 12/21/2006 | US20060286068 Polypeptides exhibiting granulocyte colony-stimulating factor (G-CSF) activity; conjugates between the polypeptides and a non-polypeptide moiety (PEG); for treatment of neutropenia or leukopenia; low in vitro bioactivity, long in vivo half-life, reduced receptor-mediated clearance |
| 12/21/2006 | US20060286066 Pegylated immunoglobulin variable region polypeptides |
| 12/21/2006 | US20060286031 Modulators of tissue regeneration |